

## Pegcetacoplan acetate

## Chemical Properties

CAS No. :

Formula: (C<sub>2</sub>H<sub>4</sub>O)<sub>n</sub>C<sub>170</sub>H<sub>248</sub>N<sub>500</sub>O<sub>4754</sub>.xC<sub>2</sub>H<sub>4</sub>O<sub>2</sub>

Molecular Weight:

Storage: Keep away from moisture,  
Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
Actual storage temperature shall be subject to the COA.

## Biological Description

Description	Pegcetacoplan acetate is a pegylated complement C3 inhibitory peptide that binds complement component 3 (C3) and its activation fragment C3b. Pegcetacoplan acetate is utilized in biomedical research focused on complement cascade regulation, complement-mediated disease modeling, and C3-dependent immune activation pathways in systems including age-related macular degeneration, C3 glomerulopathy, geographic atrophy, and autoimmune hemolytic anemia.
Targets(IC50)	Complement System
In vitro	Methods: The mechanism of action of pegcetacoplan acetate on complement C3 was analyzed, and its relevant research directions for applicable diseases were summarized. Results: Pegcetacoplan acetate targets complement C3, an upstream molecule of C5. It regulates intravascular and extravascular hemolysis, blocks C3 consumption and restores normal C3 levels, thereby remarkably alleviating proteinuria [3-4]. This agent can be studied for the treatment of various complement-related diseases, including age-related macular degeneration, C3 glomerulopathy, geographic atrophy, autoimmune hemolytic anemia and paroxysmal nocturnal hemoglobinuria [2-3].

## Solubility Information

Solubility	DMSO: 40 mg/mL, Sonication is recommended. 3 M Sodium Acetate Solution (pH 5.2): 10 mg/mL, Sonication is recommended. ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## Reference

- David S Liao, et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. *Ophthalmology*. 2020 Feb;127(2):186-195.
- Sheridan M Hoy, et al. Pegcetacoplan: First Approval. *Drugs*. 2021 Aug;81(12):1423-1430.
- Heo YA. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria. *Drugs*. 2022 Dec;82(18):1727-1735. doi: 10.1007/s40265-022-01809-w. Epub 2022 Dec 2. Erratum in: *Drugs*. 2023 Jul;83(10):949.
- Román Ortiz E, et al. Pegcetacoplan in idiopathic and familial pediatric C3 glomerulopathy. *Pediatr Nephrol*. 2025 Dec 8.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481